The role of biomarkers in cancer diagnosis, prognosis, and treatment is rapidly evolving. As knowledge about the molecular biology of cancer continues to expand, identification of actionable biomarkers (biological changes occurring in the body such as protein expression, receptors, hormones, enzymes, as well as both somatic and germline genetic mutations) continues to increase. Biomarkers (also referred to as "tumor markers" or "molecular markers") have enabled researchers to better understand cancer subtypes and to develop targeted anti-cancer therapies. The National Cancer Institute has compiled a list of commonly used biomarkers, their associated cancer types, and how the marker is used. View the list.
Presented at the 2020 ASCO Virtual Scientific Program
ACCC is conducting a survey to learn more about guideline-concordant biomarker testing, and related barriers, in patients with mCRC. Your feedback will help us better understand the impact of biomarker testing on treatment decision-making for this patient population. To be eligible to participate in this survey, you must treat at least one patient with metastatic colorectal cancer per year.
The survey will take approximately ten minutes to complete. If you respond by January 25th, your name will be entered into a drawing to win one of twenty $100 Amazon gift cards.
Complete the Survey Learn More
Through this educational program, ACCC will identify and disseminate examples of effective practices and tools for developing, implementing, and assessing operational pathways for molecular testing for eligible patients with NSCLC.